Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics

ABSTRACT Introduction : Hepatocellular carcinoma (HCC) is a malignant liver tumor characterized by high molecular heterogeneity, which has hampered the development of effective targeted therapies severely. Recent experimental data have unraveled novel promising targets for HCC treatment. Areas covered : Eligible articles were retrieved from PubMed and Web of Science databases up to July 2021. This review summarizes the established targeted therapies for advanced HCC, focusing on the strategies to overcome drug resistance and the search for combinational treatments. In addition, conventional biomarkers holding the promises for HCC treatments and novel therapeutic targets from the research field are discussed. Expert opinion : HCC is a molecularly complex disease, with several and distinct pathways playing critical roles in different tumor subtypes. Experimental models recapitulating the features of each tumor subset would be highly beneficial to design novel and more effective therapies against this disease. Furthermore, a deeper understanding of combinatorial drug synergism and the role of the tumor microenvironment in HCC will lead to improved therapeutic outcomes.

[1]  H. Shimizu,et al.  Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin‐Dependent Kinase 4/6 Inhibitor Combination Therapy , 2021, Hepatology.

[2]  B. Sangro,et al.  Advances in immunotherapy for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[3]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[4]  A. Cheng,et al.  Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages , 2021, Journal for ImmunoTherapy of Cancer.

[5]  Arturo Santos,et al.  Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models , 2021, Canadian journal of gastroenterology & hepatology.

[6]  S. Zahler,et al.  Gene editing and synthetically accessible inhibitors reveal role for TPC2 in HCC cell proliferation and tumor growth. , 2021, Cell chemical biology.

[7]  T. Decaens,et al.  Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment , 2021, International journal of molecular sciences.

[8]  C. Luo,et al.  Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism , 2020, Cancer Research.

[9]  H. Eguchi,et al.  ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma , 2020, Clinical Cancer Research.

[10]  G. Narla,et al.  Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex , 2020, PLoS biology.

[11]  Wei Zheng,et al.  CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 , 2020, Signal Transduction and Targeted Therapy.

[12]  Y. Hoshida,et al.  Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges , 2020, Journal of clinical medicine.

[13]  D. Calvisi,et al.  Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis , 2020, Cellular and molecular gastroenterology and hepatology.

[14]  Fabrice Daian,et al.  ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. , 2020, Journal of hepatology.

[15]  D. Calvisi,et al.  Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma , 2020, Gut.

[16]  H. Huynh,et al.  FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma , 2020, Experimental & Molecular Medicine.

[17]  D. Calvisi,et al.  Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis , 2020, International journal of molecular sciences.

[18]  R. Jain,et al.  Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[19]  Young Woo Cho,et al.  Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation , 2020, Molecular therapy. Nucleic acids.

[20]  G. Chen,et al.  Targeting hepatocyte growth factor/c‐mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies , 2020, Medicinal research reviews.

[21]  Shaorong Gao,et al.  Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors , 2020, Proceedings of the National Academy of Sciences.

[22]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[23]  J. Xia,et al.  Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma , 2020, British Journal of Cancer.

[24]  L. Zhong,et al.  PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma , 2020, Cancer medicine.

[25]  Xianming Deng,et al.  Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma. , 2020, European journal of medicinal chemistry.

[26]  M. Ávila,et al.  Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg , 2020, JHEP reports : innovation in hepatology.

[27]  Quy Xiao Xuan Lin,et al.  Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression , 2020, Hepatology communications.

[28]  E. Parks,et al.  Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities , 2020, Hepatology.

[29]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[30]  D. Calvisi,et al.  Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies , 2020, Hepatology.

[31]  J. Muntané,et al.  Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells , 2020, Cell Death & Disease.

[32]  D. Fan,et al.  Fibroblast Growth Factor 19–Mediated Up‐regulation of SYR‐Related High‐Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms‐Related Tyrosine Kinase 4 , 2020 .

[33]  Tao-Tao Liu,et al.  OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. , 2019, Journal of hepatology.

[34]  D. Calvisi,et al.  Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma , 2019, Front. Oncol..

[35]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Alzahrani.  PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. , 2019, Seminars in cancer biology.

[37]  Kol Jia Yong,et al.  New High-throughput Screen Identifies Compounds That Reduce Viability Specifically In Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. , 2019, Gastroenterology.

[38]  Yoon-Koo Kang,et al.  Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. , 2019, Cancer discovery.

[39]  I. Ng,et al.  Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC , 2019, Nature Communications.

[40]  J. Estall,et al.  Mitochondrial Dysfunction in the Transition from NASH to HCC , 2019, Metabolites.

[41]  T. Nishida,et al.  Glypican 3-Targeted Therapy in Hepatocellular Carcinoma , 2019, Cancers.

[42]  W. Sellers,et al.  FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer , 2019, Molecular Cancer Therapeutics.

[43]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[44]  Weiqi Zhang,et al.  Inhibition of hepatocellular carcinoma by metabolic normalization , 2019, PloS one.

[45]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[46]  M. Merad,et al.  β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. , 2019, Cancer discovery.

[47]  H. Yin,et al.  Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice , 2019, Theranostics.

[48]  Xiaomo Wu,et al.  Application of PD-1 Blockade in Cancer Immunotherapy , 2019, Computational and structural biotechnology journal.

[49]  J. Bruix,et al.  Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. , 2019, Gastroenterology.

[50]  D. Calvisi,et al.  Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans , 2019, Gut.

[51]  Wenxin Qin,et al.  Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma , 2019, Journal of Cancer.

[52]  V. Trochon-Joseph,et al.  Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model , 2018, Cancer Immunology, Immunotherapy.

[53]  Xiaolei Shi,et al.  Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts , 2018, Journal of experimental & clinical cancer research : CR.

[54]  Jin Ding,et al.  Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. , 2018, Journal of hepatology.

[55]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[56]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[57]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[58]  C. Porta,et al.  Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. , 2018, The Lancet. Oncology.

[59]  L. Qin,et al.  The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma , 2018, Journal of experimental & clinical cancer research : CR.

[60]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[61]  Chien-Feng Li,et al.  Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect , 2018, Scientific Reports.

[62]  Jeong-Hwan Kim,et al.  Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer , 2018, The Journal of clinical investigation.

[63]  P. Ward,et al.  First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial , 2018, Breast Cancer Research and Treatment.

[64]  Wei Jia,et al.  Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.

[65]  E. Raymond,et al.  Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma , 2018, Hepatology.

[66]  Christopher P. Long,et al.  Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin , 2018, Nature Communications.

[67]  M. Hao,et al.  H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. , 2017, Cancer research.

[68]  P. Hinds.  Faculty Opinions recommendation of Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. , 2017 .

[69]  Y. Liu,et al.  Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[70]  I. Fabregat,et al.  Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis , 2017, Oncotarget.

[71]  B. Ren,et al.  Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. , 2017, Cell reports.

[72]  Do-Hee Kim,et al.  Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis. , 2017, Cancer research.

[73]  D. Calvisi,et al.  Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade , 2017, PloS one.

[74]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[75]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[76]  T. Decaens,et al.  Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma , 2017, Molecular Cancer Therapeutics.

[77]  David Killock.  Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate , 2017, Nature Reviews Clinical Oncology.

[78]  Jue Wei,et al.  MiR-218 suppresses the metastasis and EMT of HCC cells via targeting SERBP1 , 2017, Acta biochimica et biophysica Sinica.

[79]  Zichen Xie,et al.  CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo , 2017, PloS one.

[80]  B. Zhai,et al.  Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells , 2017, Molecular oncology.

[81]  Suna Wang,et al.  Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma , 2017, Front. Immunol..

[82]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[83]  Miao Li,et al.  TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication , 2016, Gut.

[84]  N. Pyrsopoulos,et al.  Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date , 2016, Journal of Hepatocellular Carcinoma.

[85]  J. Llovet,et al.  Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma , 2016, Gut.

[86]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[87]  L. Terracciano,et al.  Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis , 2016, Oncotarget.

[88]  James E Audia,et al.  Histone Modifications and Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[89]  E. Erdal,et al.  Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells , 2016, Cancer science.

[90]  D. Calvisi,et al.  Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice , 2016, Scientific Reports.

[91]  D. Calvisi,et al.  Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. , 2016, Journal of hepatology.

[92]  K. Machida,et al.  NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism. , 2016, Cell metabolism.

[93]  W. Liu,et al.  Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation , 2015, Cell Death and Disease.

[94]  Lisa M. Christadore,et al.  Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model , 2015, Oncotarget.

[95]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[96]  S. Steinway,et al.  The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma , 2015, PloS one.

[97]  Fan Wang,et al.  By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice , 2015, Oncotarget.

[98]  S. Pfeffer,et al.  miR-122--a key factor and therapeutic target in liver disease. , 2015, Journal of hepatology.

[99]  I. Ng,et al.  Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis , 2014, PloS one.

[100]  N. Curtin,et al.  DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival , 2014, Clinical Cancer Research.

[101]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[102]  M. Kunnimalaiyaan,et al.  MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. , 2014, The Journal of surgical research.

[103]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[104]  B. Zhai,et al.  Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma , 2014, Molecular Cancer Therapeutics.

[105]  Jingnan Wang,et al.  Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET , 2014, Clinical Cancer Research.

[106]  D. Munn,et al.  Epitope‐optimized alpha‐fetoprotein genetic vaccines prevent carcinogen‐induced murine autochthonous hepatocellular carcinoma , 2014, Hepatology.

[107]  M. Evert,et al.  Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value , 2013, British Journal of Cancer.

[108]  M. Kudo,et al.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  H. Hurwitz,et al.  Targeted inhibition of VEGF receptor 2: an update on ramucirumab , 2013, Expert opinion on biological therapy.

[110]  G. Shi,et al.  Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. , 2013, International journal of molecular medicine.

[111]  Tyler T. Risom,et al.  Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models , 2013, Clinical Cancer Research.

[112]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[113]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[114]  Qian Wang,et al.  A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 , 2011, Clinical Cancer Research.

[115]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[116]  Paul B. Fisher,et al.  Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma , 2010, Proceedings of the National Academy of Sciences.

[117]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[118]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[119]  H. Huynh,et al.  RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[120]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[121]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[122]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[123]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[124]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[125]  Ningfei Li,et al.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. , 2017, Journal of hepatology.

[126]  T. Decaens,et al.  Effect of novel AKT inhibitor ARQ 751 as single agent and its combination with sorafenib on hepatocellular carcinoma in a cirrhotic rat model , 2017 .

[127]  Jun Yu,et al.  Histone Deacetylase HDAC 8 Promotes Insulin Resistance and b-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma , 2015 .

[128]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[129]  G. Freeman,et al.  Programmed Death-1 Ligand 1 Interacts Specifically with the B 7-1 Costimulatory Molecule to Inhibit T Cell Responses , 2022 .